Form 4: Pacira CMO Sells Shares Under 10b5-1 Plan

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold 3,960 shares of common stock for $24.09 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc. (PCRX), reported a sale of common stock.
• The transaction involved the disposition of 3,960 shares of common stock.
• The shares were sold at a price of $24.09 per share.
• The sale was executed on November 17, 2025.
• Following this transaction, Jonathan Slonin beneficially owns 178,367.009 shares of common stock directly.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was previously adopted by the reporting person.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was not based on new, non-public information and is a routine part of executive compensation and liquidity management.

Future Outlook

NA

Industry Context

Insider sales executed under a Rule 10b5-1 trading plan are common among corporate executives. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing an affirmative defense against claims of insider trading by demonstrating that the trades were not based on material non-public information.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Medical Officer under a 10b5-1 plan is generally considered a routine event and is unlikely to have a significant direct impact on the company's operational or strategic direction. It provides transparency regarding insider holdings.

Key Dates

Keywords

Pacira BioSciences, PCRX, Jonathan Slonin, Chief Medical Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan